Understanding how new drugs activate a key protein in mitochondria to help with diseases like Alzheimer's.
Elucidating the mechanism of action of novel ClpP activators in activation of the mitochondrial unfolded protein response.
This study is looking at how a special protein called ClpP helps our cells deal with stress, which is important for people with diseases like Alzheimer's and Parkinson's, and it aims to find new ways to improve cell health and slow down these conditions using new cancer drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10695884 on NIH RePORTER |
What this research studies
This research investigates the mitochondrial Unfolded Protein Response (UPRMT), a critical pathway that helps cells manage stress and is linked to degenerative diseases such as Alzheimer's and Parkinson's. The study focuses on a protein called ClpP, which is essential for removing damaged proteins in mitochondria. By using advanced techniques to analyze how ClpP is activated by novel anti-cancer drugs, the research aims to uncover mechanisms that could lead to new treatments for these conditions. Patients may benefit from insights gained about how to enhance mitochondrial function and potentially slow disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related neurodegenerative conditions.
Not a fit: Patients with non-degenerative conditions or those not diagnosed with Alzheimer's or related diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating Alzheimer's and other degenerative diseases by improving mitochondrial health.
How similar studies have performed: Previous research has shown promising results in targeting mitochondrial pathways for therapeutic benefit, indicating potential for success in this novel approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Graves, Lee M — Univ of North Carolina Chapel Hill
- Study coordinator: Graves, Lee M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.